Last reviewed · How we verify
clobetasol 0.05% cream
At a glance
| Generic name | clobetasol 0.05% cream |
|---|---|
| Sponsor | Center for Vulvovaginal Disorders |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody (PHASE2)
- Clinical Trial to Demonstrate That the Dual Laser Therapy is Effective for the Treatment of Vulvar Lichen Sclerosus (NA)
- Laser vs Clobetasol for Lichen Sclerosus (PHASE3)
- Treatment of Vulvar Lichen Sclerosus With Corticosteroid Ointment, Calcineurin Inhibitor Ointment, and Platelet-Rich Plasma (PRP) Therapy. (NA)
- ZINCLO-HAND: Zinc and Clobetasol for the Prevention of Regorafenib-Induced Hand-Foot Skin Reaction (NA)
- A Clinical Trial to Compare Topical Agents in Adults With Mild to Moderate Atopic Dermatitis (AD) (PHASE1)
- Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis (PHASE4)
- Fractional Laser and Steroid Ointment to Improve the Old Scar After Thyroidectomy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- clobetasol 0.05% cream CI brief — competitive landscape report
- clobetasol 0.05% cream updates RSS · CI watch RSS
- Center for Vulvovaginal Disorders portfolio CI